News25/Ratings0
News · 26 weeks52-25%
2025-10-262026-04-19
Mix3390d
- SEC Filings17(52%)
- Insider9(27%)
- Other6(18%)
- Offering1(3%)
Latest news
25 items- SECSEC Form 10-K filed by Profusa Inc.10-K - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- PRProfusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics PlatformCompany secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics™ multi-omics diagnostics platform from BioInsights LLC ("BioInsights"). The Company believes this acquisition, a
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form EFFECT filed by Profusa Inc.EFFECT - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form POS AM filed by Profusa Inc.POS AM - Profusa, Inc. (0001859807) (Filer)
- PRProfusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused OfferingAfter Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections BERKELEY, CA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has elected not to proceed with its public offering and intends to file a post-effective amendment with the U.S. Securities and Exchange Commission (the "SEC") for the Company's
- PRProfusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue GuidanceWith strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has received several purchase orders for the Lumee™ tissue oxygen monitoring system from its growing network of European distributors and expert physician customers. With strong underlying market
- SECSEC Form EFFECT filed by Profusa Inc.EFFECT - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form EFFECT filed by Profusa Inc.EFFECT - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 424B3 filed by Profusa Inc.424B3 - Profusa, Inc. (0001859807) (Filer)
- SECAmendment: SEC Form S-1/A filed by Profusa Inc.S-1/A - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECAmendment: SEC Form S-1/A filed by Profusa Inc.S-1/A - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form S-1 filed by Profusa Inc.S-1 - Profusa, Inc. (0001859807) (Filer)
- PRProfusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring TechnologiesCollaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual's biochemistry, has entered into a know-how agreement with Mayo Clinic. The collaboration entails investigation of high impact clinical applicatio
- SECSEC Form 424B3 filed by Profusa Inc.424B3 - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 424B3 filed by Profusa Inc.424B3 - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 424B3 filed by Profusa Inc.424B3 - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- PRProfusa Announces 1-for-75 Reverse Stock SplitBERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-seventy-five (1:75) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on February 9, 2026, and the Company's common stock will open for trading on The Nasdaq Global Market on February 9, 2026 on a
- SECProfusa Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Profusa, Inc. (0001859807) (Filer)
- INSIDERChief Financial Officer Knechtel Fred S. acquired 818,961 shares (SEC Form 4)4 - Profusa, Inc. (0001859807) (Issuer)
- INSIDERLarge owner Northview Sponsor I, Llc disposed of 4,743,750 shares, closing all direct ownership in the company (SEC Form 4)4 - Profusa, Inc. (0001859807) (Issuer)